NFE2L2 and colitis: This Nrf2 activator demonstrated that DMF could reduce the inflammatory response in experimental colitis, mainly due to the activation of Nrf2 and its downstream antioxidant genes expression after administration of DMF and simultaneously inhibit the NF-κB signaling (108).